St. Jude Medical launches PressureWwire guidewire technology in Europe.
St. Jude Medical Inc. has received CE Mark approval and launched the PressureWire X Guidewire fractional flow reserve (FFR) Measurement System in Europe.Designed to identify the severity of narrowings in the coronary arteries of patients with coronary artery disease (CAD), FFR measurement allows for a more effective assessment of coronary lesions (blockages), resulting in more accurate diagnosis. The PressureWire X guidewire European launch will include a measured rollout to targeted countries throughout 2016.
PressureWire FFR guidewire measurement supports more accurate lesion assessment during percutaneous coronary intervention (PCI) to help physicians make more informed treatment decisions for their patients, which has been shown to improve patient outcomes. The newly launched PressureWire X guidewire offers enhanced durability and improved handling in either a cabled or wireless configuration.
"Fractional flow reserve has become an indispensable tool for assessing coronary lesions and making informed treatment decisions during percutaneous coronary intervention," said Dr. Bernard De Bruyne of the CVC Aalst in Belgium. "The improved design of the new PressureWire X guidewire tip will simplify the fractional flow reserve procedure by enabling access to lesions in patients with tortuous, complex anatomy."
Designed to provide better durability and shape retention than currently available pressure guidewires, the new PressureWire X guidewire aims to provide physicians with a tip that can be shaped and re-shaped during PCI, which enables it to be used to assess multiple lesions, even in patients with complex anatomy. Allowing physicians to better navigate each patient's unique anatomy will support improved assessment and diagnosis of coronary blockages, which can lead to improved decision-making on how best to restore blood flow to the heart. The latest PressureWire X guidewire is also intended to support faster procedure times, ensuring patients undergo more efficient PCI procedures.
The use of FFR to optimize PCI is supported by strong evidence, such as the FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trials, which found that St. Jude Medical PressureWire technology can improve patient outcomes over angiography alone in patients with CAD. The FAME body of evidence also demonstrated reductions in the risk of death or heart attack in patients undergoing PCI, as well as reduced healthcare costs for patients whose treatment was guided by FFR technology.
In addition to clinical trails designed to assess the positive outcomes associated with FFR technology, St. Jude Medical has launched the PRESSUREwire Registry, a multicenter clinical trial to determine the routine use of FFR measurement and clinical outcomes of FFRguided PCI in patients with acute coronary syndrome, a major cause of global morbidity and mortality.
"St. Jude Medical strives to provide physicians with fractional flow reserve pressure guidewire options that are backed by clinical data and match the handling performance of conventional workhorse PCI guidewires, which is a combination that we have always prioritized in designing and developing the PressureWire series of FFR guidewires," said Dr. Mark Carlson, chief medical officer and vice president of global medical affairs at St. Jude Medical. "The new PressureWire X guidewire shows our dedication to providing physicians with cost-effective, easy-to-use technologies that aid them in making the best treatment decisions for their patients."
 Printer friendly
 Cite/link
 Email
 Feedback
| |
| Title Annotation: | New Technology Update |
|---|---|
| Publication: | Medical Product Outsourcing |
| Date: | Jun 1, 2016 |
| Words: | 518 |
| Previous Article: | Medtronic gets CE mark for single-chamber ICDs. |
| Next Article: | Private equity's impact on medical product outsourcing. |
| Topics: | |